Dinutuximab Beta: 8 agencies, 2017–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7 years, from 17 Oct 2017 at AWMSG (Wales) to 10 Oct 2024 at HIRA (South Korea).
HIRA (South Korea) changed its position: not recommended on 8 Aug 2024, recommended by 10 Oct 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for dinutuximab beta by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess dinutuximab beta, on 17 Oct 2017; HIRA (South Korea) did not open a file until 8 Aug 2024 — a wide spread of 6.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 11 dated records fall in 2018 alone.
2 of the 8 agencies here assessed dinutuximab beta more than once, AIFA (Italy) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for dinutuximab beta.
The full ledger for dinutuximab beta reads 7 recommended, 1 not recommended, 1 other and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 10 Oct 2024 | 코리아 소아 신경모세포종 | reimbursement appropriate | source |
| PBAC (Australia) | 2020 | Neuroblastoma | Dinutuximab beta was not considered by the PBAC at its March 2020 meeting. During the eval… | source |
| NYE METODER (Norway) | 16 Jun 2019 | Behandling av høyrisiko nevroblastom | introduced | source |
| SMC (Scotland) | 12 Nov 2018 | For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial res… | accepted | source |
| NICE (England) | 22 Aug 2018 | NICE TA538 | recommended | source |
6 further decisions for dinutuximab beta, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 11 decisions for dinutuximab beta from 8 agencies, 2017 to 2024. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.